Behind the Guidelines: Embracing LDL Goals in Dyslipidemia Management

One of the most practice-defining changes in the 2026 ACC/AHA Dyslipidemia Guideline is the formal reintroduction of absolute LDL cholesterol targets—a departure from the percent-reduction framework dominant since 2013 and a shift widely anticipated by clinicians seeking clearer benchmarks for therapeutic decision-making.

Pamela B. Morris, MD, vice chair of the guideline writing committee, explains the evidentiary basis for restoring absolute goals has strengthened considerably since 2018, with cardiovascular outcomes trials consistently demonstrating lower achieved LDL levels correspond to greater event reduction. Contemporary trials incorporating non-statin therapies have produced median LDL levels of 30–45 mg/dL in treated patients, with corresponding improvements in outcomes—reinforcing the principle lower is better across the risk spectrum.

The guideline preserves the evidence-based concept of percent LDL reduction as a measure of treatment intensity: high-intensity statin therapy targets a 50% or greater reduction, while moderate-intensity therapy targets 35–49%.

These benchmarks are now paired with specific absolute LDL cholesterol goals stratified by risk. For patients at low, borderline, or intermediate primary prevention risk, the target is less than 100 mg/dL. For high-risk primary prevention individuals, the goal is less than 70 mg/dL. For those at very high risk—including patients with established ASCVD and additional risk factors—the target is less than 55 mg/dL.

Fellow committee member Ann Marie Navar, MD, PhD, offers a straightforward clinical framework: the numbers 55, 70, and 100 correspond to highest, intermediate, and lower risk, respectively.

Navar also clarifies a nuance causing confusion in practice—these are upper thresholds, not precise targets. Patients achieving LDL levels well below the designated goal should not have therapy reduced. Across all risk categories, the evidence supports continued benefit at lower LDL concentrations, and clinicians are encouraged to pursue—not retreat from—more intensive lipid lowering whenever it is achieved.

Morris has no relevant disclosures to report. Navar reports disclosures with Amge, Arrowhead Pharmaceuticals, AstraZeneca, Bayer, Eli Lilly and Company, Esperion, Johnson & Johnson, Merck, Miga Health, NewAmsterdam Pharma, Novartis, Novo Nordisk, Sanofi, and Silence Therapeutics, among others.

References:

1. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. Published online March 13, 2026. doi:10.1016/j.jacc.2025.11.016
2. American College of Cardiology. ACC/AHA Issue Updated Guideline for Managing Lipids, Cholesterol - American College of Cardiology. American College of Cardiology. Published March 13, 2026. Accessed March 23, 2026. https://www.acc.org/About-ACC/Press-Releases/2026/03/13/18/01/ACCAHA-Issue-Updated-Guideline-for-Managing-Lipids-Cholesterol